Alpha Tau Medical ($DRTS) Stock Hub 2026: Israel GBM Update, REGAIN, ReSTART and IMPACT

01 The central question: is Alpha DaRT becoming a platform or just accumulating promising pilot data?

Alpha Tau’s investment case has broadened quickly. The company began as a development-stage story centered on a localized alpha-radiation device for accessible solid tumors. By August 2026 it had a pivotal U.S. cSCC trial fully enrolled, Japanese marketing approval in head and neck cancer, recurrent-GBM activity under an FDA-cleared U.S. study, pancreatic-cancer programs across North America and Europe, a pembrolizumab combination dataset in advanced head and neck cancer, and a Tolmar-backed U.S. prostate program.

That breadth is an advantage only if evidence quality improves as the portfolio expands. A platform is not validated because many trials exist; it is validated when the mechanism repeatedly produces clinically meaningful outcomes, the safety profile remains usable, regulators accept the data packages, physicians can insert the sources reliably, manufacturing scales, and reimbursement supports adoption.

02 Alpha DaRT: what the technology is designed to do

Alpha DaRT stands for Diffusing Alpha-emitters Radiation Therapy. The device uses intratumorally inserted sources impregnated with radium-224. As radium-224 decays, short-lived daughter atoms are released and diffuse within the tumor while emitting high-energy alpha particles.

The intended advantage is physical. Alpha particles have very high relative biological effectiveness but a short tissue range. Alpha Tau’s design seeks to generate a lethal radiation field inside a solid tumor while limiting radiation exposure to surrounding healthy tissue. The system is therefore fundamentally different from systemic radiopharmaceuticals that circulate throughout the body.

The practical constraint is equally important: Alpha DaRT requires source placement in or around the tumor. Its addressable market depends not only on cancer biology but also on whether clinicians can access the lesion by direct insertion, endoscopic ultrasound, surgery or another image-guided route.

03 Pipeline map: which programs matter most now

04 IMPACT: enrollment is complete — and the relevant number is 48, not 50

On August 31 Alpha Tau announced completion of enrollment in IMPACT, a prospective, multicenter, open-label pilot of intratumoral Alpha DaRT combined with first-line standard-of-care chemotherapy in newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma.

The study was originally approved for 12 patients and was expanded three times. The company’s final enrollment announcement states that 48 patients were enrolled and treated across 10 centers in the United States, Canada and Israel. That company-filed number is the authoritative completed enrollment figure for this update.

Alpha DaRT is delivered once as an add-on while patients continue full-dose first-line chemotherapy with either mFOLFIRINOX or gemcitabine plus nab-paclitaxel. Sources are inserted into the primary pancreatic tumor under real-time endoscopic ultrasound guidance.

The design is strategically important because Alpha Tau is not asking physicians to choose local alpha therapy instead of first-line systemic treatment. It is testing whether a one-time local intervention can add value on top of the standard regimen.

The registry record last posted August 27 still says recruiting with 50 estimated participants. The later August 31 company announcement supersedes that enrollment estimate: 48 enrolled and treated.

05 REGAIN: recurrent GBM is the most powerful headline — and the easiest one to over-read

REGAIN is a prospective, open-label, single-arm, multicenter study evaluating Alpha DaRT in recurrent glioblastoma. ClinicalTrials.gov lists a planned enrollment of 10 subjects, actual study start in October 2025, estimated primary completion in November 2026 and estimated study completion in December 2026.

In May, Alpha Tau reported results from the first three U.S. patients treated at Ohio State: 100% local disease control, a 67% complete-response rate by RANO criteria and one associated grade 3 serious adverse event, with no unanticipated associated serious adverse events. The FDA subsequently reviewed the prespecified interim safety report and cleared enrollment of the final seven patients, and Alpha Tau added two U.S. sites.

The FDA clearance is an execution and safety-review milestone. It does not validate the efficacy rate. Three patients are far too few to estimate a stable response probability, and recurrent GBM is heterogeneous, heavily pretreated and difficult to compare across small uncontrolled cohorts.

On June 23, Alpha Tau announced the first Israeli recurrent-GBM patient under the broad-access ALL protocol. The September 9 Hebrew letter adds an additional Hadassah treatment without a procedure date, explicit distinct-patient count or new safety/efficacy results. It does not specify the additional procedure’s protocol. The English letter omits that additional procedure. Do not add Israeli treatments to REGAIN’s U.S. efficacy denominator. June 23 · Hebrew letter · English letter · Social interpretation

06 ReSTART: the pivotal U.S. path

ReSTART is the most important U.S. regulatory program because it is Alpha Tau’s pivotal trial in recurrent cutaneous squamous cell carcinoma and the company has already begun a modular PMA process with the FDA.

Enrollment of all 88 patients was completed on May 8, 2026 across U.S. and selected international centers. ClinicalTrials.gov now lists the trial as active, not recruiting.

The study is prospective, multicenter, single-arm and open-label. The co-primary endpoints focus on confirmed objective response and durability of response, while secondary measures include local control, progression-free survival, overall survival and quality of life.

Alpha DaRT has FDA Breakthrough Device Designation in recurrent cSCC. That designation can facilitate regulatory interaction but does not lower the requirement to produce an acceptable benefit-risk package.

Alpha Tau guides ReSTART topline data to late 2026 or early 2027.

Registry reconciliation, checked September 9: ClinicalTrials.gov still lists estimated enrollment of 86 and estimated completion in April 2027. The May 8 company announcement confirms 88 enrolled; the August guidance for topline in late 2026/early 2027 is distinct from registry study completion.

07 ADMIRE: extending recurrent cSCC into immunocompromised patients

On July 15 Alpha Tau announced treatment of the first patient in ADMIRE at Banner MD Anderson Cancer Center. The study evaluates intratumoral Alpha DaRT in immunocompromised patients with recurrent cutaneous squamous cell carcinoma.

This population matters because immunocompromised patients can face more aggressive cSCC and may have different treatment constraints. ADMIRE also builds on the clinical and operational infrastructure established through ReSTART rather than representing a completely separate technology path.

The first-patient treatment is an execution milestone, not efficacy evidence. The relevant future questions are enrollment pace, safety in the immunocompromised population and whether response characteristics are consistent with the broader recurrent-cSCC experience.

08 Head and neck cancer: the pembrolizumab combination signal

On July 21 Alpha Tau reported complete top-line results from a single-center Phase 1/2 study of Alpha DaRT combined with pembrolizumab in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma.

All nine response-evaluable patients achieved a systemic RECIST 1.1 response: four complete responses and five partial responses. Median overall survival was 18.2 months and median progression-free survival was 5.4 months. The company compared those figures with historical pembrolizumab-monotherapy benchmarks of 19% ORR, 12.3 months median OS and 3.2 months median PFS.

The systemic-response aspect is what makes the dataset strategically interesting: the company’s thesis is not only that Alpha DaRT can destroy the injected tumor, but that local tumor irradiation may complement checkpoint inhibition and contribute to responses away from the treated site.

But this is a nine-patient evaluable dataset from a single center, with no randomized pembrolizumab-only comparator. Cross-trial historical comparisons are hypothesis-generating, not proof of incremental contribution.

Alpha Tau has said it is discussing a similar, larger U.S. study with the FDA.

09 Japan: the first marketing approval changes the company — but not into a U.S. commercial-stage biotech

In February 2026 Japan’s Ministry of Health, Labour and Welfare granted Shonin marketing approval for Alpha DaRT in unresectable locally advanced or locally recurrent head and neck cancer. This was Alpha Tau’s first regulatory marketing approval outside Israel.

The approval followed PMDA review and creates a real commercial pathway in Japan. It also comes with a required post-market surveillance study of 66 patients at five selected leading Japanese clinical centers.

The Japan milestone is important validation of manufacturability, clinical usability and a regulator’s benefit-risk assessment. It does not mean Alpha DaRT has FDA approval, U.S. reimbursement or a proven large-scale sales model.

10 Tolmar and prostate cancer: the first major partnered U.S. commercialization route

The June 3 collaboration with Tolmar materially changed the business-development profile. Tolmar received exclusive U.S. commercialization rights for prostate cancer, with an option to expand into bladder cancer subject to additional payments. Alpha Tau leads clinical development in collaboration with Tolmar and remains responsible for manufacturing and supply.

A U.S. safety study of intratumoral Alpha DaRT in locally recurrent prostate cancer is registered with an estimated enrollment of 12 patients. Alpha Tau’s August update continued to target first U.S. patient treatment in the second half of 2026.

The partnership reduces the need for Alpha Tau to build a full U.S. uro-oncology sales organization alone, but development risk and regulatory risk remain with the program before commercial economics can materialize.

The prostate registry, last updated April 6, still says not yet recruiting. No newer first-U.S.-patient announcement was found in the company newsroom as of September 9; H2 2026 remains guidance.

11 Pancreatic cancer beyond IMPACT: ACAPELLA and Verona create a global evidence network

IMPACT is not Alpha Tau’s only pancreatic program. The company has generated first-in-human pancreatic experience in Israel and Canada, operates ACAPELLA in France and has treated patients at the University of Verona in Italy.

Earlier 2026 presentations at DDW and ASCO reported favorable safety and encouraging survival observations across different pancreatic-cancer settings. Those data helped support the decision to use Alpha DaRT as a one-time add-on alongside full-dose first-line chemotherapy in IMPACT.

The European studies matter because they test different clinical workflows, disease stages and delivery approaches. The challenge is analytical heterogeneity: pooled small studies with different lines of therapy and patient selection should not be treated as a single randomized efficacy dataset.

The most useful near-term evidence will be the prospectively followed 48-patient IMPACT cohort, because it is larger and more structured than the early exploratory experience.

12 Financial baseline: the company has more liquidity, but it is still pre-revenue

Total assets were $134.250 million and total liabilities $90.195 million at June 30, leaving $44.055 million of shareholders’ equity. A $47.537 million warrant liability explains much of the fall in book equity despite the improved cash balance.

13 Cash flow: why the $(0.7)M first-half operating cash use needs context

Alpha Tau reported only $745,000 of negative operating cash flow in the first half of 2026, dramatically smaller than the GAAP net loss. That headline is mechanically correct and economically easy to misread.

The Tolmar transaction created $18.878 million of deferred revenue on the balance sheet. The company received $15 million toward U.S. manufacturing and accounted for approximately $3.9 million of equity consideration in excess of the fair value of shares issued as part of the transaction price. No product revenue was recognized against those amounts because the relevant performance obligation had not yet been satisfied.

Working-capital timing and the non-cash warrant remeasurement further separate cash flow from GAAP net income.

14 Capital structure: shares, warrants and the ATM

Ordinary shares issued and outstanding rose from 88,009,737 at December 31, 2025 to 92,332,873 at June 30, 2026. The August 10 TASE registration used 92,478,154 outstanding shares.

The Tolmar private placement itself added 1,668,057 shares at $11.99 per share. The company also has outstanding public and private warrants and equity awards that can create additional shares.

At June 30, 13,605,561 public warrants and 2,142,000 private warrants remained outstanding, each generally exercisable into one ordinary share at $11.50 subject to their terms. The warrant liability stood at $47.537 million because the share-price move materially increased fair value.

Alpha Tau also entered into an at-the-market sales agreement with H.C. Wainwright in April 2026 allowing the company to sell up to $100 million of ordinary shares from time to time under the shelf registration framework. Capacity is not the same as issuance; future periodic filings must be checked for actual ATM use.

15 Insider activity: the CFO’s August 21 exercise-and-sale fits a 10b5-1 pattern

A Form 4 filed August 25 reports that CFO Raphi Levy exercised options for 2,871 ordinary shares on August 21 at $2.98 and sold the same 2,871 shares that day at a weighted-average price of $15.0028, leaving 90,180 directly held ordinary shares.

The filing is part of a broader 2026 series of CFO option exercises and sales. A Rule 144 notice filed August 21 identifies planned sales activity under a Rule 10b5-1 trading plan adopted March 24, 2026.

Pre-arranged exercise-and-sale transactions are not analytically identical to a discretionary open-market sale of long-held shares. They still represent insider selling and belong in the record, but the plan structure and option exercise should accompany the headline.

SEC submissions checked September 9: the latest issuer filing is the August 31 IMPACT 6-K; the latest listed Form 4 remains the August 25 CFO filing.

16 Management, governance and execution risk

Alpha Tau is led by Chief Executive Officer Uzi Sofer. The company’s scientific foundation originates with Prof. Itzhak Kelson and Prof. Yona Keisari, whose work on diffusing alpha emitters underpins the platform.

The execution burden is now materially larger than it was one year ago. Management must run multiple multicenter trials, mature a pivotal PMA package, support Japanese post-market surveillance, build U.S. manufacturing capacity, coordinate a major commercialization partner and maintain capital discipline at the same time.

The Tolmar partnership reduces one future commercial-build burden in U.S. uro-oncology, but the company remains responsible for clinical development and manufacturing. As the pipeline broadens, site activation, isotope/source logistics, production quality and clinical operations become as important as scientific novelty.

The Nasdaq/TASE dual listing adds another investor base and local trading hours, but it does not change voting economics or create cash by itself.

17 Market data and valuation context

Stocktwits quoted DRTS at $14.62 on September 9, 2026 at 1:09 p.m. ET, an intraday snapshot rather than a closing price. Multiplying by the 92,478,154 shares reported August 10 gives approximately $1.35 billion. The share denominator is historical and excludes subsequent changes; this is not a current fully diluted capitalization.

The market value is already far above book equity and current revenue cannot be used as a denominator because Alpha Tau remains essentially pre-product-revenue. The stock therefore trades on probability-weighted future commercialization rather than existing earnings.

Exchange-reported short-interest data for August 14 show approximately 3.06 million shares short, or about 5.6% of public float, with roughly 6.1 days to cover according to MarketBeat’s presentation of the settlement-date data. This is meaningful but not an extreme squeeze setup by itself.

Analyst price targets are especially weak as a valuation anchor here because target methodologies must assign probabilities and economics to multiple unapproved programs. A target that changes after one early dataset can move far more than the underlying cash balance.

18 Retail sentiment: bullish, with normal message volume

Stocktwits snapshot September 9, 2026, 1:09 p.m. ET: canonical sentiment 62/100 — Bullish, normalized message volume 49/100 — Normal, and 3,246 watchers. The tagged-message subset was 100% bullish, which is a different measure and does not represent every investor. Recent messages discuss the CEO letter and upcoming clinical updates; these posts are sentiment evidence, not independent clinical verification.

19 Scenario framework for 2026–2027

20 Red flags and thesis-breakers

• REGAIN efficacy weakening materially as the denominator expands beyond the first three patients.
• Unexpected serious safety events involving source placement, radiation effects or procedure-related complications.
• ReSTART topline failing to show adequate confirmed responses and durability for a credible PMA path.
• FDA requests that materially expand the ReSTART evidence burden or delay modular PMA progress.
• IMPACT data slipping beyond early 2027 or failing to support a rational pivotal design.
• The first U.S. prostate treatment slipping beyond H2 2026 without a clear operational explanation.
• Japan post-market surveillance revealing a materially different safety or effectiveness profile.
• Rapid ATM use or another large equity raise before major value-inflecting data, unless clearly matched by accretive strategic funding.
• Warrant exercises and equity awards expanding fully diluted shares faster than clinical value.
• Tolmar manufacturing milestones or U.S. capacity falling behind the clinical-development timeline.

21 Evergreen monitoring checklist

22 Merlintrader bottom line

Alpha Tau is materially more advanced than it was at the beginning of 2026. It has one real marketing authorization in Japan, a fully enrolled U.S. pivotal cSCC trial, a GBM program cleared by the FDA to finish enrollment after an interim safety review, an expanded pancreatic program that has now completed enrollment at 48 patients, a provocative head-and-neck immunotherapy-combination dataset and a U.S. commercial partner in Tolmar for prostate cancer.

The August 31 IMPACT milestone improves execution credibility because a trial that was originally designed for 12 patients was expanded three times and still completed 48-patient enrollment. It also removes one near-term milestone from the future-tense list. The next question is no longer whether IMPACT can recruit; it is what the 48-patient dataset shows in early 2027 and whether the company can design a credible pivotal study from it.

The strongest part of the bull case is breadth plus repeated execution. The strongest part of the bear case is evidence maturity. ReGAIN’s striking percentages come from three patients; the head-and-neck systemic ORR comes from nine evaluable patients; pancreatic evidence remains non-randomized; and ReSTART still has to translate a completed pivotal enrollment into a regulatory-quality outcome.

Financially, the $104.8 million liquidity balance gives the company room, but the first-half cash-flow statement is unusually influenced by Tolmar deferred revenue and non-cash warrant accounting. Alpha Tau remains a pre-revenue company with an active ATM framework, large warrant overhang and an expanding trial budget.

The cleanest scorecard from here is four-part: REGAIN around year-end 2026, ReSTART late 2026/early 2027, IMPACT early 2027, and capital discipline throughout the interval. If those clinical programs mature while the share denominator remains controlled, DRTS can increasingly be underwritten as a multi-indication platform. If pivotal evidence disappoints or financing outruns clinical progress, the current market value leaves less room for error.

23 Related Merlintrader research

• Top Ten Biotech Stocks Right Now
• Free Biotech / Tech Catalyst Calendar